NCT04385992View on ClinicalTrials.gov

Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 9, 2020

Primary Completion Date

January 25, 2023

Study Completion Date

June 26, 2023

Conditions
Neuroendocrine Tumors
Interventions
DRUG

177Lu-Dotatate

Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE

Trial Locations (1)

20132

Ospedale San Raffaele, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER

NCT04385992 - Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET | Biotech Hunter | Biotech Hunter